Corbus制药控股 CRBP 深 沪
等待开盘 02-04 09:30:00 美东时间
8.09
-0.190
-2.29%
华盛通- 最 高8.39
- 今 开8.34
- 成交量 8.38万股
- 最 低 8.02
- 昨 收 8.28
- 总市值 9914.46万
- 52周最高 20.56
- 市盈率 静 --
- 换手率 0.68%
- 52周最低 4.64
- 委 比 -19.32%
- 总股本 1225.52万
- 历史最高 323.40
- 量 比 0.54
- 振 幅 4.47%
- 历史最低 3.00
- 每 手 1
- 风险率 2.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Corbus Updates Corporate Outlook, Highlights Diversified 2026 Pipeline
An announcement from Corbus Pharmaceuticals ( ($CRBP) ) is now available. On Ja...
01-12 20:45
Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company in oncology and obesity, announced that its CEO, Yuval Cohen, Ph.D., will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2026. The presentation will highlight Corbus' pipeline, including CRB-701, CRB-601, and CRB-913, and will be available via webcast. The company is headquartered in Norwood, Massachuset...
01-05 12:30
Corbus Pharmaceuticals To Release Phase 1a Results For Obesity Drug CRB-913 On December 11, 2025
Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical stage company focused on oncology and obesity, announced the Company's plan to release results of its Phase 1a single ascending dose (SAD) and multiple
2025-12-11 05:01
Wedbush Initiates a Buy Rating on Corbus Pharmaceuticals (CRBP)
Wedbush analyst initiated coverage with a Buy rating on Corbus Pharmaceuticals ...
2025-11-14 21:57
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
RBC Capital Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $53
RBC Capital analyst Brian Abrahams maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $55 to $53.
2025-11-14 01:33
Corbus Pharmaceuticals Advances Oncology and Obesity Pipeline
Corbus Pharmaceuticals Holdings ( ($CRBP) ) has released its Q3 earnings. Here ...
2025-11-13 12:50
Corbus Pharmaceuticals Q3 EPS $(1.90) Misses $(1.72) Estimate
Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.90) per share which missed the analyst consensus estimate of $(1.72) by 10.72 percent. This is a 65.22 percent decrease over losses of $(1.15) per
2025-11-12 21:08
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
Corbus Pharmaceuticals Holdings, Inc., a company focused on oncology and obesity, announced its participation in three upcoming investor conferences: Guggenheim’s Healthcare Innovation Conference in Boston on November 12, Jefferies Global Healthcare Conference in London on November 18, and Evercore’s Healthcare Conference in Miami on December 2. The company, headquartered in Norwood, Massachusetts, specializes in developing innovative therapies t...
2025-11-06 13:00
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Alphatec Holdings (NASDAQ:ATEC) shares rose 21.7% to $19.88 during Fri...
2025-10-31 20:10
